Tanya Dorff, MD, City of Hope Comprehensive Cancer Center
Articles
Emerging Therapies for Advanced Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Genetic Testing in Metastatic CRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Impact of Clinical Data on the Treatment of mCRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
The CARD and PROfound Trials for Metastatic CRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Differences Between AR-Targeted Therapy in Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Overall Survival Data Presented at ASCO 2020 for nmCRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
FDA Approved Agents for Non-Metastatic CRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Clinical Trials in the Community Setting for Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Data for Metastatic Castration-Sensitive Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Conventional Versus PSMA Imaging in Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
PSMA-Targeted Imaging in Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Dr. Dorff on Role of Chemotherapy in mCRPC
October 6th 2016Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.
Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
